Q&A with Richard Shor, President of SaniSure - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Q&A with Richard Shor, President of SaniSure
Q&A with Richard Shor, President of SaniSure.

Pharmaceutical Technology
Volume 36, Issue 12


Richard Shor

PharmTech:

How has the increasing focus on biopharmaceuticals affected your business?

Shor:

In the sense that biopharmaceuticals are now a growth industry as opposed to the traditional chemical–pharmaceutical industry, it has impacted us greatly. Single-use process components are ideal for the biopharmaceutical arena. Batches are typically smaller and most of the processes are not using chemicals that will affect the components we provide.

PharmTech:

How will the industry remain innovative as it reduces spending on research?

Shor:

We have not seen any decline in innovations; however, it is now coming from other sources. What we are seeing is the partnership and licensing of a molecule to a start-up or small biotechnology company. This model allows the big companies to reduce their R&D budgets and risk exposure while allowing the smaller companies to get funding through private equity or other sources. If the product is a success, the investors win as well as the large biotechnology companies that will purchase the smaller company in the end.

PharmTech:

Do you see a new industry trend emerging?

Shor:

Regulatory compliance has become a big part of our customers' requirements. Biotechnology companies are demanding much tighter control and assurance of our products. As a supplier of single-use components and systems, SaniSure is now being asked to have control of our supplier base and the raw materials they are using. The onus is on us to assure a consistent and stable level of quality and control.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here